RT Journal Article SR Electronic T1 Nedaplatin and Irinotecan in Patients with Large-cell Neuroendocrine Carcinoma of the Lung JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1453 OP 1456 VO 32 IS 4 A1 YOSHIYUKI KENMOTSU A1 FUMIHIRO OSHITA A1 MAKIKO SUGIURA A1 SHUJI MURAKAMI A1 TETSURO KONDO A1 HARUHIRO SAITO A1 KOUZO YAMADA YR 2012 UL http://ar.iiarjournals.org/content/32/4/1453.abstract AB Background: No standard chemotherapy has been established for patients with large-cell neuroendocrine carcinoma (LCNEC). Patients and Methods: Patients with LCNEC of the lung were treated with nedaplatin (NP) at 50 mg/m2 and irinotecan at 50 mg/m2 on days 1 and 8 every four weeks for four cycles. Results: Data for 18 of the LCNEC patients were retrospectively analyzed. All patients were male, with a performance status 0 or 1, and the median age was 68 (range 58-80) years. Nine patients received adjuvant chemotherapy after undergoing complete surgical resection. Fourteen patients were able to receive four cycles of nedaplatin and irinotecan. Grade 4 leukopenia and neutropenia occurred in 5.6% and 16.7%, respectively. Four patients experienced grade 3 non-hematologic toxicities, such as diarrhea, enterocolitis, duodenal perforation and myocardial infarction. There were no treatment-related deaths. Two patients achieved complete response and four achieved partial response, and the median survival time was 12.3 months for the nine patients with advanced disease. Conclusion: Nedaplatin plus irinotecan is effective and safe for patients with LCNEC of the lung.